NCT00482755 2024-02-12
Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
Canadian Cancer Trials Group
Phase 2 Completed
Clinical Trials
13 trialsNCT02019303 2022-11-01
Accuracy of FNA Versus CNB of Abnormal Axillary Lymph Nodes in Setting of Invasive Breast Cancer
University of Utah
Phase NA Completed
NCT04759053 2021-02-17
Effectiveness of Core-Needle US Guided Biopsy as Primary Tool For Diagnosis of Thyroid Nodules
Kafrelsheikh University
Phase NA Completed
NCT03273426 2020-04-09
Prediction of pCR by Preoperative Biopsy in Breast Cancer With cCR After Neoadjuvant Chemotherapy.
Seoul National University Hospital
Phase NA Completed
NCT01259089 2019-09-11
Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
Northwestern University
Phase 1/2 Completed
NCT00804245 2018-07-03
C-11 Choline PET-CT Scan in Finding Metastases in Patients With Newly Diagnosed High-Risk Prostate Cancer
Wake Forest University Health Sciences
Phase 1 Completed
NCT00194779 2018-03-12
Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery
University of Washington
Phase 2 Completed
NCT00466752 2017-11-22
Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer
University of Washington
Phase 2 Completed
NCT00715793 2017-10-03
UPCI-07-008
University of Pittsburgh
Phase 1/2 Completed
NCT01855503 2016-11-17
MAP-IT
Yale University
Completed
NCT00316823 2014-02-24
Genetic Analysis in Diagnosing Thyroid Cancer in Patients With Thyroid Nodules
National Cancer Institute (NCI)
Phase NA Completed
NCT00918788 2013-08-22
Laser Spectroscopy of Breast Tissue Through a Needle Device
Case Comprehensive Cancer Center
Completed
NCT00673569 2010-08-09
Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed